Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: Rationale for combined use of CK2- and γ-secretase inhibitors

Haematologica

Volumn 95, Issue 4, 2010, Pages 674-678

  Silva, Ana ^a   Jotta, Patrícia Y ^b   Silveira, André B ^b   Ribeiro, Daniel ^a   Brandalise, Silvia R ^b,c   Yunes, J Andrés ^b   Barata, João T ^a  

^a UNIVERSITY OF LISBON   (Portugal)

^b CENTRO INFANTIL BOLDRINI   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

CK2 inhibitors; NOTCH1; Protein stabilization; T ALL

Indexed keywords

4,5,6,7 TETRABROMOBENZOTRIAZOLE; 5,6 DICHLOROBENZIMIDAZOLE RIBOSIDE; AMIPHENAZOLE; BENZOTRIAZOLE DERIVATIVE; CASEIN KINASE II; CASEIN KINASE II INHIBITOR; GAMMA SECRETASE INHIBITOR; MESSENGER RNA; MYC PROTEIN; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHILD; CONTROLLED STUDY; DOWN REGULATION; ENZYME REGULATION; FLOW CYTOMETRY; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T CELL LEUKEMIA; WESTERN BLOTTING;

AMYLOID PRECURSOR PROTEIN SECRETASES; BLOTTING, WESTERN; CASEIN KINASE II; CELL PROLIFERATION; CELL SIZE; CHILD; DICHLORORIBOFURANOSYLBENZIMIDAZOLE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; MUTATION; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PTEN PHOSPHOHYDROLASE; RECEPTOR, NOTCH1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRIAZOLES;

EID: 77950668038     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.011999     Document Type: Article

References (17)

1. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306(5694): 269-71.
2. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007;13(10):1203-10.
3. Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A, et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature. 2007;447(7147): 966-71.
4. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M, et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest. 2008; 118(11):3762-74.
5. Barata JT, Boussiotis VA, Yunes JA, Ferrando AA, Moreau LA, Veiga JP, et al. IL- 7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL. Blood. 2004;103(5):1891-900.
6. Breit S, Stanulla M, Flohr T, Schrappe M, Ludwig WD, Tolle G, et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood. 2006;108(4): 1151-7.
7. Sulis ML, Williams O, Palomero T, Tosello V, Pallikuppam S, Real PJ, et al. NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood. 2008;112(3):733-40.
8. Barata JT, Silva A, Brandao JG, Nadler LM, Cardoso AA, Boussiotis VA. Activation of PI3K Is Indispensable for Interleukin 7- mediated Viability, Proliferation, Glucose Use, and Growth of T Cell Acute Lymphoblastic Leukemia Cells. J Exp Med. 2004;200(5):659-69.
9. Barata JT, Cardoso AA, Nadler LM, Boussiotis VA. Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1). Blood. 2001;98(5):1524-31.
10. Sharma VM, Calvo JA, Draheim KM, Cunningham LA, Hermance N, Beverly L, et al. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol Cell Biol. 2006;26(21):8022-31.
11. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C, et al. C-Myc is an important direct target of Notch1 in Tcell acute lymphoblastic leukemia/lymphoma. Genes Dev. 2006;20(15):2096-109.
12. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, et al. NOTCH1 directly regulates c-MYC and activates a feedforward- loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA. 2006;103(48):18261-6.
13. Larson Gedman A, Chen Q, Kugel Desmoulin S, Ge Y, Lafiura K, Haska CL, et al. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia. 2009;23(8):1417-25.
14. Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E, et al. Gammasecretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med. 2009;15(1):50-8.
15. Solares AM, Santana A, Baladron I, Valenzuela C, Gonzalez CA, Diaz A, et al. Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies. BMC Cancer. 2009;9:146.
16. Gonzalez-Garcia S, Garcia-Peydro M, Martin-Gayo E, Ballestar E, Esteller M, Bornstein R, et al. CSL-MAML-dependent Notch1 signaling controls T lineage-specific IL-7R{alpha} gene expression in early human thymopoiesis and leukemia. J Exp Med. 2009;206(4):779-91.
17. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell. 2008;133(3):403-14.